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a b s t r a c t 
We report a case of ventricular septal defect (VSD) in which we attempted to treat pulmonary arterial 
hypertension (PAH) with the goal of VSD closure in an adult with suspected Eisenmenger syndrome in 
childhood. Four years previously (age 41 years), she was referred to our department due to repeated 
hemoptysis requiring further treatment of PAH. We started combination therapy with several pulmonary 
vasodilators. Two years later, her pulmonary vascular resistance (PVR) was improved but still not at the 
level where VSD closure was possible. To control the increased PA flow resulting from intensive PAH 
treatment and to reduce the risk of hemoptysis, we performed pulmonary artery banding (PAB). As the 
risk of hemoptysis decreased, a prostacyclin analog was introduced, and the dose was increased. More 
than 1 year after PAB, active vasoactivity testing became positive, suggesting that the pulmonary vascular 
lesion was now “reversible”. We performed VSD closure and atrial septal defect creation even though her 
PVR was still high. After the operation, her exercise capacity was remarkably improved. We suggest that 
stepwise surgical repair with pulmonary vasodilators is an important treatment option for select patients 
with VSD with severe PAH. 
Learning objective 
Advances in pulmonary arterial hypertension (PAH) treatment have led to the use of a “treat-and-repair”
strategy to close the intracardiac shunt after PAH treatment in select patients with adult congenital heart 
disease. In our case, ventricular septal defect (VSD) closure was achieved with stepwise surgical repair 
and a combination of pulmonary vasodilators, even though long-standing severe PAH with persistent 
hemoptysis remained. Even after a long period of exposure to high blood flow, this strategy may reduce 
pulmonary vascular resistance and permit eventual closure of the VSD. 
© 2021 Japanese College of Cardiology. Published by Elsevier Ltd. 
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Recent advances in disease-targeted therapy (DTT) for pul- 
onary arterial hypertension (PAH) have improved the exercise ca- ∗ Corresponding author. 





878-5409/© 2021 Japanese College of Cardiology. Published by Elsevier Ltd. This is an op
 http://creativecommons.org/licenses/by-nc-nd/4.0/ ) 
Please cite this article as: A. Kanai, N. Koitabashi, S. Akagi et al., A 
complicated by severe pulmonary hypertension-stepwise surgical repair
//doi.org/10.1016/j.jccase.2021.02.013 acity and survival in patients with unrepaired congenital heart 
isease (CHD) with PAH. The “treat-and-repair” or “treat-to-close”
trategy, which is shunt closure after intensive PAH treatment with 
TT, has been applied for adult patients with advanced CHD-PAH, 
nd has resulted in favorable outcomes in limited numbers of pa- 
ients, especially those with atrial septal defect (ASD) [1] . Recently, 
he “treat-and-repair” strategy has been tried even in ventricular en access article under the CC BY-NC-ND license 
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Table 1 
Serial cardiac catheter examinations. 
Catheter examination(The 
numbers correspond to 
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SAP (mmHg (mean)) NA 92/60 (73) 97/50 (67) 97/57 (73) 99/52 (68) 108/56 (76) 84/54 (64) 
PAP (mmHg (mean)) 96/40 (64) 93/38 (61) 91/34 (57) 94/30 (50) 82/32 (51) 95/27 (52) 60/25 (38) 
RVP (syst/EDP, mmHg) 101/15 91/10 85/7 98/13 90/10 94/7 57/10 
mRAP (mmHg) 9 4 5 7 8 4 9 
PAWP (mmHg) 12 7 12 8 9 9 9 
Qp/Qs 1.52 1.54 1.3 1.98 1.53 1.53 1.24 
PVR (WU) 11.3 9.6 10.8 9 7.7 11.3 8.3 
PVRI (WUm 2 ) 16.9 14.1 15.9 13.2 11.3 15.3 11.6 
SVR (WU) NA NA 19.7 27.5 17.6 26.7 18.8 
Rp/Rs NA NA 0.55 0.33 0.43 0.43 0.44 
DPG (mmHg) 28 31 22 22 23 18 16 
SaO 2 (%) 95 96 92 96 97 97 98 
AVT NA NA Response (-) Response (-) Response (-) Response ( + ) Response (-) 
Plasma BNP level (pg/mL) 23.6 26.5 18.2 34.6 39.7 42.3 154.7 
VSD, ventricular septal defect; SAP, systemic arterial pressure; PAP, pulmonary arterial pressure; RVP, right ventricular pressure; syst/EDP, systolic RV pressure/RV end- 
diastolic pressure; mRAP, mean right atrial pressure; PAWP, pulmonary arterial wedged pressure; Qp/Qs, pulmonary-systemic flow ratio; PVR, pulmonary vascular resis- 
tance; PVRI, pulmonary vascular resistance index; SVR, systemic vascular resistance; Rp/Rs, pulmonary vascular resistance/systemic vascular resistance ratio; DPG, diastolic 
pressure gradient (diastolic PAP-PAWP); SaO2, oxygen saturation; AVT, acute vasoreactivity testing; BNP, B-type natriuretic peptide; NA, not applicable. 









































































eptal defect (VSD) patients with advanced PAH [2] . Most previ- 
us studies reported VSD patients with severe PAH whose baseline 
ulmonary vascular resistance index (PVRI) was more than 8 wood 
nits (WU) ∗m 2 . This level was previously considered a contraindi- 
ation for surgical repair [3] . 
ase report 
A 41-year-old female patient with non-restrictive VSD was re- 
erred to our hospital from another hospital. At age 7 years, she 
as diagnosed with VSD for the first time. Her diagnostic catheter 
xamination showed a mean pulmonary arterial pressure (PAP) of 
7 mmHg, l -R shunt of 98%, and R-L shunt of 64%. Pediatric car- 
iologists suspected that she had already developed Eisenmenger 
yndrome, and her VSD was not indicated for surgery at age 8 
ears. From age 20 years, she was hospitalized due to hemoptysis 
ne or two times per year. At age 25 years, home oxygen therapy 
as administered. At age 30 years, bosentan, an endothelin recep- 
or antagonist, was started, but hospitalization due to hemoptysis 
as repeated. At age 41 years, she was referred to our hospital be- 
ause hemoptysis had worsened. 
She was 157 cm tall and weighed 48 kg. Her physical activity 
as estimated as World Health Organization functional class III. 
lubbed fingers and cyanosis were observed. Chest X-ray ( Fig. 1 a ) 
nd electrocardiogram ( Fig. 1 a ) showed enlargement of the PA 
nd right ventricular (RV) hypertrophy. Echocardiogram showed 
erimembranous VSD (16 mm in diameter) with both directional 
nhunt flow but mainly an l -R shunt ( Fig. 1 c–f ). The size of the
SD compared to that in her childhood was unclear. RV and left 
entricular systolic functions were maintained ( Online Table 1 ). 
The overall time course is shown in Fig. 2 a . The first catheter
xamination in our hospital showed severe PAH, including a mean 
AP of 64 mmHg, pulmonary-systemic flow ratio (Qp/Qs) of 1.52, 
nd PVRI of 16.9 WU ∗m 2 ( Table 1 - 1 ©). Because combination ther-
py with DTT is effective in reducing pulmonary vascular resis- 
ance (PVR) in patients with PAH [4] , we added riociguat, a stimu- 
ator of soluble guanylate cyclase, and changed bosentan to maci- 
entan. Catheter examination 5 months after the treatment change 2 howed an improvement in PAH. Her mean PAP was 61 mmHg, 
p/Qs was 1.54, and PVRI was 14.1 WU ∗m 2 ( Table 1 - 2 ©). How-
ver, hemoptysis had worsened, and repeated catheter examina- 
ion (5 months after the previous examination) showed that the 
ean PVRI had worsened to 15.9 WU ∗m 2 ( Table 1 - 3 ©), but the di-
stolic pressure gradient (DPG: diastolic PAP-PA wedged pressure), 
nother marker for PVR [5] , had improved. We performed acute 
asoreactivity testing (AVT) with oxygen administration, but no re- 
ponse was observed (Online Table 2). Before this catheter exam- 
nation, we performed cardiac magnetic resonance (CMR) imaging 
 Online Table 3 ). RV ejection fraction estimated with CMR imaging 
as 70%, suggesting that RV function was maintained. RV size re- 
ained in the normal range but the RV mass index (35.0 g/m 2 ) 
howed RV hypertrophy [6] . We switched her medication from 
iociguat to tadalafil, a phosphodiesterase 5 inhibitor. Repeated 
atheter examination after 1 year showed an improvement in PVRI 
13.5 WU ∗m 2 ) and in Qp/Qs (1.3 → 1.98) ( Table 1 - 4 ©); however, her
VR was still high, and she showed no response with AVT ( Online 
able 2 ). To control the increased PA flow resulting from inten- 
ive PAH treatment and to reduce the risk of hemoptysis, we per- 
ormed pulmonary artery banding (PAB) [7] . Because the RV func- 
ion was preserved, it was decided that PAB would be feasible. Her 
ain PA was constricted with an elastic band with a median ster- 
otomy approach (the detailed method is described in the Online 
ext). Echocardiography after PAB showed that distal PA systolic 
ressure was physically reduced more than 30 mmHg compared 
o RV systolic pressure. Although PAB reduced the distal PAP, it in- 
reased the R-L shunt and worsened hypoxia in her systemic circu- 
ation. An increased amount of oxygen administration was required 
mmediately after PAB due to hypoxia ( Fig. 2 ). Interestingly, sys- 
emic hypoxia gradually improved within 1–2 months after surgery 
Online Fig. 1 ). In addition to macitentan and tadalafil, a prosta- 
yclin receptor agonist, selexipag, was started after PAB. The pa- 
ient’s 6 min walk test (6MWT) distance was improved with in- 
reased oxygenation (1.5 to 2 L/min) ( Fig. 2 ). A catheter examina- 
ion 1 year after PAB showed a substantial reduction in PVR (PVRI 
1.3 WU ∗m 2 ), but the AVT response was modest ( Table 1 - 5 ©, On-
ine Table 2 ). No increase in RV end diastolic pressure (RVEDP) 
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Fig. 1. Chest X-ray ( a ) and electrocardiogram ( b ) when the patient was referred to our hospital; ( c –f) Echocardiography when the patient was referred to our hospital. 
Ventricular septal defect is indicated with the white arrow. The defect diameter was estimated as 16 mm; ( c) Parasternal long-axis view; ( d) Apical five chambers view with 


























r right atrial pressure (RAP) occurred, suggesting that right heart 
ailure had not developed. We continued the treatment with DTT 
nd followed her with echocardiogram and catheter examinations 
 Table 1 , Online Tables 1 and 2 ). RV function was maintained even
fter PAB. Plasma B -type natriuretic peptide was not increased. Al- 
ost 1.5 years after PAB, catheter examination was performed. PAP 
proximal position of PAB) was still high, but the DPG had im- 
roved (23 to 18 mmHg), and AVT showed a significant response 
o oxygen exposure ( Table 1 - 6 ©, Online Table 2 ) [8] . Her baseline
VR was 11.4 WU, but oxygen exposure reduced PVR to 6.2 WU, 
epresenting a 45.6% decrease. The gradual decrease in pulmonary 
rterial resistance and the increase in vasoreactive response sug- 3 ested the possibility of partial recovery of pulmonary vascular re- 
odeling. Selexipag was switched to continuous transvenous infu- 
ion of the prostacyclin, epoprostenol. Surgical closure of VSD and 
SD creation with a penetrated patch were successfully performed 
ith a PA-debanding procedure. Four weeks after surgery, catheter 
xamination was performed ( Table 1 - 7 ©, Online Table 2 ). Aver- 
ge PAP and PVRI were markedly improved (52 to 38 mmHg and 
5.3 to 11.6 WU ∗m 2 , respectively). Echocardiogram showed no VSD 
hunt flow and successful VSD closure ( Fig. 2 b and c ) and main-
enance of RV systolic function but decreased RV diastolic function 
stimated by RV-E/e’ (Online Table 1 ). Resting oxygen saturation 
as markedly improved. The 6MWT distance improved to 354 m 
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Fig. 2. (a) A time course of this case. Stars indicate hospitalization for severe hemoptysis. The numbers for catheter examination are detailed in Table 1 . ( b) and ( c) 
Echocardiography after VSD closure. The closed VSD portion is indicated with a white arrow. ( b) Parasternal long-axis view; ( c) Parasternal short-axis view. 6MWT, six-minute 
walk test, walk distance (m) is described with minimum SpO 2 during exercise. The 6MWTs were performed under oxygenation as described below, whereas the test marked 
with ∗ was performed without oxygenation; NA, not applicable; WHO-FC, World Health Organization functional class; PAB, pulmonary artery banding; ERA, endothelin 
receptor antagonist; PDE5i, phosphodiesterase 5 inhibitor; sGCS, soluble guanylate cyclase stimulator; PGI2A/IPRA, prostaglandin I2 analog/prostaglandin I2-receptor agonist; 






































ithout oxygenation. Six months after the operation, she contin- 
ed to do well with DTT. 
iscussion 
A treat-and-repair strategy is thought to be more difficult in pa- 
ients with PAH associated with VSD than in those with ASD. In 
atients with large VSD, pulmonary circulation is connected to the 
V, resulting in high pressure and high flow, whereas ASD is asso- 
iated with low pressure and high-flow PA pathology due to a pre- 
ricuspid shunt [9] . The dynamic high pressure of VSD contributes 
o the progression of pulmonary artery lesions and the susceptibil- 
ty to Eisenmenger syndrome. This pathophysiology is closely re- 
ated to the difficulty of PAH treatment in patients with VSD-PAH. 
ystolic PAP must remain unchanged even if PVR decreases due 
o DTT in patients with VSD [10] . Therefore, treatment with DTT 
ould easily cause hemoptysis and/or heart failure. In this case, 
AB was performed prior to VSD closure because hemoptysis re- 
ccurred when intensive DTT was introduced. PAB can physically 
educe the pressure load on the periphery of the PA, and may sup- 
ort “reverse remodeling” of pulmonary hypertensive lesions of the 4 A vasculature [ 2 , 4 ]. Although the usefulness of PAB for the treat-
nd-repair strategy in VSD remains controversial [10] , it was ef- 
ective for reducing the hemoptysis risk during DTT combination 
herapy in this case. 
After long-term combination therapy with DTT and PAB, our 
ase showed a positive AVT response in terms of a more than 20% 
ecrease in PVR, but the final PVRI was still higher than 8 WU ∗m 2 .
herefore, our case was obviously challenging. Although continua- 
ion of DTT was mandatory, postoperative hemoptysis did not oc- 
ur, cyanosis disappeared, and exercise tolerance has improved. 
This report has several limitations. First, AVT is mainly used 
o determine whether surgical closure can be performed in pedi- 
tric shunting heart disease, and its significance in adult CHD re- 
ains unclear [9] . Further experience will be required to confirm 
he significance. Second, we did not observe any pathological ev- 
dence of “reverse remodeling” in the PA. PVR was gradually re- 
uced, and the AVT response became positive after long-term com- 
ination therapy with DTT and PAB in this case. The clinical course 
uggested that “reverse remodeling” of the PA may be achieved, 
ut this idea is still speculation. Third, this is the report of one 
ase. This treat-and-repair for VSD-PAH is still a challenging strat- 
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In conclusion, we report a middle-aged patient with VSD and 
evere PAH who was diagnosed with Eisenmenger syndrome in 
hildhood. Even after a long period of exposure to high blood flow, 
pfront combination therapy with DTT and PAB may reduce PVR 
nd permit eventual closure of the VSD. Further experience is re- 
uired, but we suggest that stepwise surgical repair with DTT is 
n important treatment option for select patients with VSD, even 
hose diagnosed with Eisenmenger syndrome, if the pulmonary 
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